Concepedia

Miren Zamacona

MZ

Statistics

Publications

11

Citations

470

H-Index

10

Active since

1997

Affiliations

UCB Pharma (United Kingdom)(Current)

University of the Basque Country

Charité - Universitätsmedizin Berlin

Miren Zamacona is an author at UCB Pharma (United Kingdom) specializing in pharmacology, pharmacokinetics, and protein binding.

Publications per year

1997–2018

11

Publications

11

Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles

Chris Chamberlain, Peter Colman, Ann Ranger et al. · Annals of the Rheumatic Diseases · 2017 · 105 citations

, , +17

First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus

Adina Tocoian, Peter Buchan, Hishani Kirby et al. · Lupus · 2015 · 74 citations

, , +17

Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942

Gary Burgess, Malcolm Boyce, Margaret M. Jones et al. · EBioMedicine · 2018 · 58 citations · Full text

, , +17

Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models

Justin Earp, Wojciech Krzyżański, Abhijit Chakraborty et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2004 · 44 citations

, , +14

Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding

Emma Davé, Ralph Adams, Oliver Zaccheo et al. · mAbs · 2016 · 43 citations · Full text

, , +17

1–5 of 11